GH
T2Guardant Health, Inc.
OverviewGuardant Health develops blood tests and data solutions for cancer care. Its oncology tests, like Guardant360 and Reveal, guide treatment and monitor advanced a
Guardant Health develops blood tests and data solutions for cancer care. Its oncology tests, like Guardant360 and Reveal, guide treatment and monitor advanced and early-stage cancers. The Shield test offers early cancer detection, notably for colorectal cancer. The company also partners with biopharma for companion diagnostics and data insights. In 2025, oncology represented ~70% of revenue, biopharma ~21%, and screening ~8%, serving physicians, patients, and pharmaceutical firms.
- What They Do (Plain English & Analogies)
- Guardant Health is a company that helps doctors fight cancer using advanced blood tests, often called "liquid biopsies." Instead of needing a piece of tissue from a tumor, they can find tiny fragments of cancer DNA in a patient's blood. This allows doctors to choose the best treatments, monitor if those treatments are working, and even screen for cancer early, like for colorectal cancer. Think of it like a highly sensitive "bloodhound" for cancer, sniffing out even the smallest traces of the disease to guide patient care.
- Very Brief History
- Guardant Health, Inc. was incorporated in 2011 and co-founded by Helmy Eltoukhy and AmirAli Talasaz. The company has become a leader in precision oncology, launching products like Guardant360 for advanced cancer. Key milestones include receiving Medicare coverage for Guardant Reveal for CRC surveillance in early 2025, the first full year for Shield IVD in 2025, and the acquisition of MetaSight Diagnostics in December 2025 to expand into multi-disease detection.
- "Street Stereotype"
- Guardant Health is generally perceived as a leading innovator in precision oncology, particularly in the liquid biopsy space. They are seen as a company that has successfully built out a strong technological platform and data network, leveraging infrastructure developed during the ZIRP era. Investors view them as a key player in the shift towards personalized medicine and early cancer detection, with significant growth potential in centralized lab diagnostics, especially with their Shield colorectal cancer screening test. They are also recognized for their integration of AI into their data-rich workflows.
- Subsidiaries On Linked In*
- Based on available information, no separate subsidiary brands are explicitly shown on LinkedIn as distinct entities with their own profiles. However, Guardant Health recently acquired MetaSight Diagnostics in December 2025.
- Customer Sectors & Example Clients
- Guardant Health's customers are primarily in the healthcare sector, including oncologists, primary care physicians, and health systems. They also serve biopharmaceutical companies and medical institutions. Specific example clients mentioned include Merck (for companion diagnostics and novel therapies), Quest Diagnostics (for national sales and connectivity system integration for Shield), and PathGroup (expanding Shield's reach to health systems).
- New Customers / Segments They'Re Targeting
- Guardant Health is actively targeting several new customer segments and markets. This includes earlier-stage cancer patients by expanding Guardant Reveal for therapy monitoring in late-stage cancer and pursuing additional reimbursement coverage for breast cancer surveillance, immuno-oncology monitoring, and chemo monitoring. They are also aiming for asymptomatic individuals for multi-cancer detection by expanding Shield to include a multi-cancer detection results report for 9 common cancers. Furthermore, they are focusing on large health systems for Shield integration and expanding globally, such as for Guardant360 CDx in Italy and exploring self-pay Shield in select markets outside the U.S. With the acquisition of MetaSight Diagnostics, they are also targeting multi-disease detection beyond oncology, including conditions like liver disease-associated fibrosis, myocardial infarction, and diabetic kidney disease.
- How Key Themes May Help/Hurt
- Guardant Health is significantly helped by the 'Infra Built in ZIRP: HC Platforms' theme, as their established infrastructure and data networks from the ZIRP era provide efficiencies and cost advantages, enabling them to capitalize on the growing demand for innovative diagnostics. The 'AI '25: Data Owners' theme is a major benefit, as their proprietary and constantly updating datasets, combined with their Infinity AI learning engine, create a strong competitive moat for therapeutic discovery and biomarker development. The 'MedTech Long '25: Centralized Lab Diagnostics' theme is also highly favorable, with CMS premium pricing (ADLT) and broad Medicare coverage for Shield driving substantial test volume growth. However, they could be hurt by higher interest rates impacting future R&D, intensifying competition leading to pricing pressure, and regulatory/reimbursement risks such as potential CLFS cuts or delays in approvals. The risk of commoditized AI models or tightening data privacy regulations could also limit the utility of their AI-driven initiatives.
3 Main Long-Term Bull Details
- Dominant Position in Liquid Biopsy & Expanding Portfolio: Guardant Health has established a leading position in liquid biopsy for oncology with Guardant360, Reveal, and Shield. The continuous rollout of new "Smart Platform" applications, expansion of Reveal into therapy monitoring, and the multi-cancer detection capabilities of Shield create a compounding flywheel, driving deeper clinical adoption and synergistic ordering patterns across the care continuum.
- Strong Commercial Execution & Reimbursement: The company has demonstrated exceptional commercial execution, particularly with Shield, achieving ADLT status and securing a favorable reimbursement rate, leading to rapid volume and revenue growth. Strategic partnerships with Quest Diagnostics and PathGroup, along with ongoing efforts for additional Medicare coverage for Reveal and potential ACS guideline inclusion for Shield, are expected to further accelerate adoption and market penetration.
- Data Moat & AI-driven Innovation: Guardant Health's rapidly deepening and diversifying data repository, combined with its Infinity AI learning engine, provides a significant competitive advantage. This data-driven approach accelerates therapeutic discovery, biomarker development, and reinforces their clinical franchise, enabling continuous innovation and expansion into new areas like multi-disease detection through acquisitions like MetaSight Diagnostics.
3 Main Long-Term Bear Details
- Intensifying Competition & Pricing Pressure: The liquid biopsy and cancer screening markets are highly competitive, with existing players and new entrants vying for market share. This could lead to pricing pressure, particularly as ADLT grace periods end or if new, cheaper technologies emerge, impacting Guardant Health's profitability and market position.
- Reimbursement & Regulatory Risks: While Guardant Health has secured significant reimbursement, ongoing changes in regulatory policies (e.g., CLFS cuts, LDT rules) and the need for continuous evidence generation for new indications and products (e.g., Reveal, Shield MCD) pose risks. Any adverse reimbursement decisions or delays in regulatory approvals could significantly impact revenue and growth.
- Execution Risk in Scaling & New Market Entry: Scaling up commercial operations for Shield, integrating new technologies like MetaSight, and successfully entering new markets (e.g., multi-cancer detection, international expansion, multi-disease detection) present significant execution challenges. Failure to effectively manage these expansions or achieve anticipated clinical utility and adoption could lead to higher costs and lower-than-expected returns.
- Competitors And Differentiation
- Guardant Health's competitors include Exact Sciences (with Cologuard for CRC screening), Personalis (for MRD), Grail (with Galleri for multi-cancer detection), and other companies in the liquid biopsy and genomic testing space. Guardant Health differentiates itself through a comprehensive portfolio spanning treatment selection (Guardant360), monitoring (Reveal), and screening (Shield), enabling a more holistic view of the patient journey. Their "Smart Platform" and Infinity AI learning engine, coupled with a rapidly growing data repository, drive continuous innovation and accelerate therapeutic discovery. They emphasize generating strong clinical evidence to support adoption and reimbursement, and aim for best-in-class sensitivity with products like the upcoming Reveal Ultra. Strategic partnerships and the recent acquisition of MetaSight Diagnostics, which brings complementary mass spectrometry technology, further enhance their competitive positioning and expand their multi-disease detection capabilities.
- Recent Performance & What The Market'S Focused On
- Guardant Health delivered strong financial results in 2025, with full-year revenue of $982 million, representing 33% year-over-year growth. Q4 2025 revenue was $281 million, up 39% year-over-year. Oncology revenue grew 26% for the full year to $683.6 million, with volumes up 34%. Biopharma and data revenue grew 18% to $210.1 million. Screening revenue (Shield) totaled $79.7 million from 87,000 tests in its first full year. Non-GAAP gross margin improved to 66% for the full year. Adjusted EBITDA loss improved to $220.9 million for the full year. Free cash flow burn was $233 million, an improvement of $42 million, with the core business (excluding screening) generating positive free cash flow in Q3 and Q4 2025. The market is keenly focused on the accelerating expansion of Shield, with 2026 revenue guidance of $162 million to $174 million (210,000 to 225,000 tests). Key drivers include the impact of collaborations with Quest and PathGroup, potential ACS guideline inclusion, and the ramp-up of their commercial team. Investors are also tracking the continued strong growth in the oncology business, particularly Reveal's expansion into therapy monitoring and the launch of new products like Reveal Ultra and Guardant360 Liquid CDx. The company's path to profitability and achieving company-wide cash flow breakeven by the end of 2027 is a significant focus. The integration and potential of the MetaSight acquisition for multi-disease detection is also a new area of interest.
- Brands And Revenue Segments
- Brands include Guardant360 (Liquid, LDT, CDx, Tissue), GuardantOMNI, GuardantINFORM, Guardant Reveal (including Reveal Ultra), Shield (including multi-cancer detection report), GuardantConnect, Guardant-19, and MetaSight Diagnostics (acquired technology). Revenue Segments (Full Year 2025): * Oncology: $683.6 million (70% of total revenue) * Biopharma and Data: $210.1 million (21% of total revenue) * Screening: $79.7 million (8% of total revenue)
Bull / Bear DetailsGuardant Health presents a compelling bullish investment case as of 2026-03-03, driven by its breakout 2025 performance and robust 2026 outlook. The company lev
Thesis
Guardant Health presents a compelling bullish investment case as of 2026-03-03, driven by its breakout 2025 performance and robust 2026 outlook. The company leverages its advanced oncology Smart Platform and rapidly scaling Shield screening business, which achieved ADLT status and high adherence. Strategic partnerships, AI-driven data insights, and a clear path to profitability for its core business underpin sustained growth and market leadership in precision oncology and early cancer detection.
Bull case
Guardant's oncology business is experiencing exceptional growth, with Guardant360 volumes up nearly 30% year-over-year due to Smart Platform applications. Reveal is the fastest-growing oncology product, benefiting from Medicare coverage for CRC surveillance and early uptake in therapy monitoring, with further reimbursement submissions pending for breast cancer, immuno-oncology, and chemo monitoring. [cite: Helmy Eltoukhy]
The Shield colorectal cancer screening test is a significant multiyear growth driver, achieving ADLT status with a $1,495 reimbursement rate secured through 2027 and a remarkable 93% real-world adherence rate. Strategic collaborations with Quest Diagnostics and PathGroup are set to broaden its national reach and drive substantial volume growth in 2026, with revenue projected to increase from $80 million to $162-$174 million. [cite: AmirAli Talasaz, Michael Bell]
Guardant Health is demonstrating a clear path to profitability and strong financial management. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with a commitment to company-wide cash flow breakeven by the end of 2027. Operational efficiencies, including the NovaSeq X transition for Guardant360 liquid by mid-2026, are expected to improve gross margins. [cite: Michael Bell]
Bear case
The Shield screening business continues to incur significant cash burn, projected at around $220 million for 2026, similar to 2025. This heavy investment in commercial infrastructure, while strategic, delays overall company-wide free cash flow positivity and introduces execution risk in scaling the sales force and integrating new partnerships effectively. [cite: Michael Bell, AmirAli Talasaz]
While Shield's ADLT rate is stable, its average selling price (ASP) is expected to decline in 2026 due to a changing mix, with increasing demand from the under-65 commercial population. This mix shift could impact overall revenue per test and gross profit, potentially offsetting some volume gains if commercial reimbursement rates are lower or less consistent than Medicare. [cite: Michael Bell]
The company's guidance for 2026 does not include potential upside from Quest co-promotion activities or ACS guideline inclusion for Shield, indicating these are not guaranteed or fully realized catalysts. Furthermore, the broader multi-cancer early detection (MCED) field faces evolving regulatory and evidence generation challenges, as highlighted by a competitor's recent trial not meeting its primary endpoint. [cite: AmirAli Talasaz, Paul Stewardson]
Bull / Bear Case
- Bear Case
- The Shield screening business continues to incur significant cash burn, projected at around $220 million for 2026, similar to 2025. This heavy investment in commercial infrastructure, while strategic, delays overall company-wide free cash flow positivity and introduces execution risk in scaling the sales force and integrating new partnerships effectively. While Shield's ADLT rate is stable, its average selling price (ASP) is expected to decline in 2026 due to a changing mix, with increasing demand from the under-65 commercial population, potentially impacting overall revenue per test and gross profit. The company's guidance for 2026 does not include potential upside from Quest co-promotion activities or ACS guideline inclusion for Shield, indicating these are not guaranteed or fully realized catalysts. Furthermore, the broader multi-cancer early detection (MCED) field faces evolving regulatory and evidence generation challenges, as highlighted by a competitor's recent trial not meeting its primary endpoint. [cite: Michael Bell, AmirAli Talasaz, Paul Stewardson]
- Bull Case
- Guardant Health's oncology business is experiencing exceptional growth, with Guardant360 volumes up nearly 30% year-over-year due to Smart Platform applications. Reveal is the fastest-growing oncology product, benefiting from Medicare coverage for CRC surveillance and early uptake in therapy monitoring, with further reimbursement submissions pending for breast cancer, immuno-oncology, and chemo monitoring. The Shield colorectal cancer screening test is a significant multiyear growth driver, achieving ADLT status with a $1,495 reimbursement rate secured through 2027 and a remarkable 93% real-world adherence rate. Strategic collaborations with Quest Diagnostics and PathGroup are set to broaden its national reach and drive substantial volume growth in 2026, with revenue projected to increase from $80 million to $162-$174 million. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with a commitment to company-wide cash flow breakeven by the end of 2027, supported by operational efficiencies like the NovaSeq X transition improving gross margins. [cite: Helmy Eltoukhy, AmirAli Talasaz, Michael Bell]
- More Compelling & Why
- Bear. Despite strong revenue growth, Guardant Health's current Price-to-Sales ratio of approximately 12-15x is significantly higher than its estimated fair value (5.9x) and industry peers (1.3-1.5x). The strongest argument for the bear case is the continued heavy cash burn for the Shield business (projected ~$220 million in 2026) and the expected decline in Shield's ASP due to mix shift, which, combined with the high valuation and recent stock underperformance, makes the stock vulnerable to execution missteps or delays in achieving company-wide profitability [cite: Michael Bell, 2]. My view would flip to bull if the company demonstrates a faster-than-expected reduction in Shield's cash burn or if the stock price corrects to a P/S ratio closer to its fair value or industry average.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| ACS Guideline Inclusion for Shield | Inclusion of Shield in the American Cancer Society (ACS) guidelines would significantly broaden the recommended use of the test, expanding the addressable market beyond Medicare-covered lives and accelerating adoption, particularly among younger patient populations and in states with screening mandates. This is a major unguided upside. | Official announcement from the American Cancer Society regarding updated colorectal cancer screening guidelines that explicitly include blood-based tests like Shield as a recommended option. | Bullish if ACS guidelines are updated to include Shield as a recommended screening option, leading to increased payer acceptance and broader clinical adoption. | American Cancer Society (ACS) official website for guideline updates, and Guardant Health press releases. | Medical journal publications and industry news discussing updates to colorectal cancer screening guidelines. | |
| Guardant360 Liquid CDx FDA Approval and ESR1 Monitoring Test Launch | FDA approval for Guardant360 Liquid CDx would enable concurrent ordering of liquid and tissue biopsies, addressing a current headwind and potentially boosting Guardant360 tissue volumes. The launch of the ESR1 monitoring test expands the therapy monitoring franchise, both representing potential upsides not included in 2026 guidance. | Official announcement of FDA approval for Guardant360 Liquid CDx. Announcement of the commercial launch and initial uptake metrics for the ESR1 monitoring test. | Bullish if FDA approval for Guardant360 Liquid CDx is received in 2026. Bullish if the ESR1 monitoring test launches and demonstrates strong early adoption. | Guardant Health press releases, SEC filings (10-Q/K), and FDA announcements. | Industry news on companion diagnostics approvals and new oncology test launches. | |
| NovaSeq X Transition for Guardant360 Liquid | The successful and timely transition of Guardant360 liquid tests to the NovaSeq X platform is crucial for improving operational efficiency and expanding gross margins. This directly impacts Guardant Health's profitability and its stated path to company-wide cash flow breakeven by the end of 2027. | Management commentary on the progress and completion of the NovaSeq X transition for Guardant360 liquid tests, which is expected around mid-2026. Monitor Guardant360 gross margin in subsequent earnings reports. | Bullish if the transition is completed on schedule (around mid-2026) and results in the expected 200 basis point improvement in Guardant360 gross margin, pushing it into the low 70% range. Bearish if delays occur or margin improvements are less than anticipated. | Guardant Health's quarterly earnings calls and press releases. | ||
| Reveal Reimbursement Expansion (MolDx Submissions) | Successful Medicare reimbursement for additional Reveal indications (breast cancer surveillance, immuno-oncology monitoring, chemo monitoring) will significantly expand Reveal's addressable market, drive test volumes, and improve average selling prices, accelerating oncology revenue growth. | Announcements from MolDx or Guardant Health regarding positive coverage decisions for the submitted data packages for breast cancer surveillance, immuno-oncology monitoring, and chemo monitoring. | Bullish if MolDx grants positive coverage decisions for any of the submitted indications, providing upside to Reveal ASP and volume. | Guardant Health press releases, SEC filings (10-Q/K), and the MolDx website for coverage updates. | Industry news and medical publications tracking MolDx coverage decisions for similar ctDNA tests. | |
| Shield Volume Growth from Quest Diagnostics and PathGroup Collaborations | Shield is a key multiyear growth driver. Collaborations with Quest Diagnostics and PathGroup are critical for expanding national reach and commercial infrastructure, directly impacting Shield test volumes and revenue beyond current guidance. | Monitor sequential Shield test volumes reported quarterly. Look for specific updates on the ramping productivity of sales reps and the impact of Quest co-promotion activities, which are not included in current guidance. | Bullish if sequential Shield test volume growth significantly exceeds the Q4 2025 increase of 14,000 tests, particularly in the first half of 2026. Bullish if Quest co-promotion activities are explicitly cited as contributing meaningfully to volume. | Guardant Health's quarterly earnings calls and press releases. Updates from Quest Diagnostics or PathGroup regarding the collaboration. | Google Trends: 'Guardant Shield' or 'blood cancer screening'. Industry news on diagnostic partnerships and market penetration. | Thinknum: Sales job postings for Guardant Health (screening sales reps) to gauge commercial build-out pace. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Oncology Revenue | This is the largest revenue segment, driven by new Smart Platform applications and Reveal's growth. Continued strong performance is crucial for overall company growth and profitability path. | 30% |
| Total Revenue | Total revenue reflects the combined success across all business segments and is a primary indicator of the company's overall top-line execution and progress towards its long-range targets. | 39% |
Key QuestionsWill Guardant Health's Shield test achieve its projected sequential volume growth in Q1 2026, particularly with the initial impact of Quest and PathGroup collab
Will Guardant Health's Shield test achieve its projected sequential volume growth in Q1 2026, particularly with the initial impact of Quest and PathGroup collaborations offsetting typical PCP seasonality?
- Question 2
Will Guardant Health secure additional Medicare reimbursement for Reveal in new indications (breast MRD, IO/chemo monitoring) and successfully launch Guardant360 Liquid CDx and the ESR1 monitoring test in the near term, driving oncology segment upside?
- Question 3
Can Guardant Health demonstrate a clear trajectory towards its 2026 free cash flow burn target of $185-$195 million, effectively balancing continued heavy investments in Shield with improving profitability in the core business?
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Driving adoption and expanding capabilities in oncology**: Management highlighted exceptional growth in their oncology business due to new capabilities and insights from Smart Platform applications, including Guardant360 Liquid, Guardant360 tissue upgrades, and Medicare coverage for Reveal in CRC surveillance. They are also excited about Reveal for therapy monitoring and its synergistic potential with Guardant360. [cite: Helmy Eltoukhy] 2. **Scaling the Shield screening business**: Management emphasized Shield's extraordinary growth since launch, driven by strong demand, the expansion of their commercial organization, and strategic partnerships with Quest Diagnostics and PathGroup. They also noted the securing of ADLT pricing. [cite: AmirAli Talasaz, Michael Bell] 3. **Strengthening path to profitability and improving cash flow**: Management reported improved non-GAAP gross margin and reduced free cash flow burn. They expect the core business (excluding screening) to be free cash flow positive for the full year 2026 and are committed to achieving company-wide cash flow breakeven by the end of 2027. [cite: Michael Bell] | The overall takeaway from the call is that Guardant Health delivered strong financial results in Q4 and full-year 2025, driven by robust performance in its oncology business and the rapid scaling of its Shield screening product. Management provided an optimistic outlook for 2026, projecting continued strong revenue growth and emphasizing strategic investments in key growth drivers, particularly in screening. They also highlighted a clear path to profitability for the core business and a commitment to company-wide cash flow breakeven by the end of 2027. The tone of the call was **positive and confident**, underscoring strong execution, successful product launches, and impactful strategic partnerships, while also acknowledging the necessary ongoing investments in the screening segment. | In Q3 2025, total revenue increased 39% Y/Y. Oncology revenue grew 31% Y/Y. Biopharma and data revenue increased 18% Y/Y. Screening revenue grew 2310% Y/Y (from $1.0 million in Q3 2024 to $24.1 million in Q3 2025). | 1. **Reveal therapeutic monitoring opportunity**: Analysts asked about the opportunity for Reveal therapeutic monitoring for both Reveal and Guardant360 volumes. Management responded that it's a significant opportunity to work synergistically with Guardant360, bridging to subsequent Guardant360 tests as patients progress, and that reimbursement wins for IO and chemo monitoring could be important growth drivers. [cite: Daniel Leonard, Helmy Eltoukhy] 2. **Shield specific burn and sales rep hiring pace**: Analysts inquired about the expected free cash flow burn for Shield and the pace of sales rep hiring. Management stated that Shield's burn for 2026 is expected to be similar to 2025 (around $220 million) due to continued heavy investments in commercial infrastructure. They plan to continue building out the commercial organization by reinvesting incremental gross profit into sales and marketing. [cite: Douglas Schenkel, Michael Bell, AmirAli Talasaz] 3. **Shield ASP decline and international contribution**: Analysts questioned the guided decline in Shield's average selling price (ASP) and the expected international contribution. Management explained that the ASP decline is primarily due to a mix impact from increasing demand from the under-65 population (non-Medicare), despite the ADLT rate being maintained for Medicare. They anticipate international contribution to Shield to be relatively small in 2026, with the majority of growth coming from the U.S. [cite: Tycho Peterson, Michael Bell] | Total revenue increased 39% year-over-year (Y/Y) to $281 million. Oncology revenue grew 30% Y/Y to $190 million. Biopharma and data revenue was up 9% Y/Y to $54.0 million. Screening revenue totaled $35.1 million from approximately 38,000 Shield tests; a specific Y/Y revenue growth percentage was not provided in the transcript, but it represents a significant increase compared to 6,400 tests in the prior year period. [cite: Michael Bell, 10] |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Guardant Health introduced groundbreaking applications for Guardant360 Liquid, upgraded Guardant360 tissue onto their smart platform, and expanded Reveal to support therapy monitoring. The company applied Infinity AI to develop 15 smart applications on Guardant360 liquid, which are believed to meaningfully expand its clinical utility and leadership in the liquid CGP market. Global access was expanded in Q4 with the launch of Guardant360 CDx technology in Rome, Italy. Reveal received Medicare coverage for CRC surveillance in early 2025 and is generating clinical data for additional reimbursement coverage this year, with early uptake for late-stage therapy response monitoring broadening its clinical use. Data packages have been submitted to support coverage in breast cancer surveillance, immuno-oncology monitoring, and chemo monitoring, with ongoing studies across more than 5 additional tumor types. Shield expanded to include a multi-cancer detection results report and received TRICARE coverage for eligible average-risk individuals aged 45 and older. The company successfully deployed its first enterprise-scale integrations with large health systems in West Virginia and Georgia and announced collaborations with Quest Diagnostics and PathGroup to broaden national reach in 2026. There are also plans for expansion of self-pay Shield into select markets outside the U.S. In biopharma, Guardant Health is a leader in companion diagnostics with 25 approvals and a robust pipeline, including 5 new CDx approvals for Guardant360 in the last 6 months, and a multiyear agreement with Merck. | Guardant Health believes it is building a meaningful competitive moat in its oncology business through the combined strength of Guardant360 and Reveal, being uniquely positioned with scaled offerings spanning both treatment selection and monitoring. Shield's 93% adherence rate represents a meaningful improvement compared to other screening modalities, which typically range from 25% to 71%. The upcoming Reveal Ultra is expected to redefine sensitivity in the tumor-informed space. The company noted that a competitor's large multi-cancer early detection (MCED) trial did not meet its primary endpoint in terms of looking for stage shift. | There is a growing role for blood-based monitoring in cancer care. Legislation establishing a Medicare coverage pathway for multi-cancer detection tests has recently passed. The broader industry is experiencing a shift towards personalized medicine and early cancer detection, driving increased demand for advanced diagnostic solutions. CMS premium pricing (ADLT) and broad Medicare coverage for blood-based CRC and follow-on Cologuard 2, along with the Trump-era rollback of LDT rules, are accelerating payer uptake of ctDNA/MCED and AI-enabled pathology. | For full year 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing 27% to 30% growth, positioning them to achieve their 2028 long-range revenue target of $2.2 billion. Oncology revenue growth is projected at 25% to 27% in 2026, with volume growth of approximately 30%, and Reveal is expected to remain the fastest-growing oncology product. Biopharma and data revenue is forecasted for low double-digit growth in 2026. Screening revenue is expected to be in the range of $162 million to $174 million from 210,000 to 225,000 tests in 2026. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with the company committed to achieving company-wide cash flow breakeven by the end of 2027. Free cash flow burn for 2026 is anticipated to improve to $185 million to $195 million. Upcoming oncology product launches include Guardant360 Liquid CDx, an ESR1 monitoring test, and Reveal Ultra. In screening, the company anticipates inclusion in ACS guidelines, commercial expansion with Quest, and international self-pay Shield expansion. The transition of Guardant360 liquid tests to NovaSeq X is expected to be fully implemented around the middle of 2026. | **HC | 2025 was a breakout year for Guardant, where years of investment continues to fuel breakthrough innovation and best-in-class execution across our portfolio. This exceptional performance reflects continued broad-based growth across our oncology screening and biopharma and data businesses. Shield is the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver for Guardant. We expect the core business to be free cash flow positive for the full year 2026 and remain committed to achieving company-wide cash flow breakeven by the end of 2027. We're feeling really good about how we're sort of managing the burn. | These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This is just the second year of launch, and we want to be thoughtful with our guidance. We typically don't want to get too excited and get ahead of our skis just based on 1 quarter performance. Q1 seasonality in PCP offices is kind of normal. Our screening guidance does not include potential upside from Quest co-promotion activities as well as ACS guideline inclusion. | Guardant Health significantly expanded its commercial team and established strategic partnerships to meet growing demand for blood-based screening. The commercial organization for Shield scaled throughout 2025, exiting the year with approximately 300 sales reps, and will continue to build out in 2026, with incremental gross profit invested in sales and marketing, primarily for building the sales force and hiring more people. The acquisition of MetaSight Diagnostics also brought on an impressive team, strengthening the world-class R&D organization. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-19 | Guardant Health reported strong Q4/FY25 revenue and volume growth, with Shield exceeding expectations and the core business achieving positive free cash flow. The company issued bullish 2026 guidance, projecting continued expansion and a path to profitability. However, the stock significantly underperformed the market post-earnings, suggesting investor skepticism regarding the pace of profitability or the aggressive investment in screening despite positive operational updates. | Other | Neutral | False | -3.08% (vs SPY: -2.77%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| GH_e0ac1fbd | later this quarter | 2026-02-20 | 2026-03-31 | Launch of Quest Diagnostics and PathGroup collaborations to broaden Shield's national reach, including EMR integration and potential co-promotion; a near-term catalyst for Shield volume growth. | Could materially expand Shield adoption and revenue in 2026 by accelerating access through large health systems and a national sales footprint. | Ticker | 2026-02-19 | earnings_transcript |
| GH_eb277c45 | mid-2026 | 2026-05-01 | 2026-06-30 | NovaSeq X transition for Guardant360 liquid tests; cost per test expected to drop and gross margins to improve toward the low-to-mid 70% range. | Margin improvement and cost efficiency could meaningfully enhance profitability and free cash flow in 2026 and beyond. | Ticker | 2026-02-19 | earnings_transcript |
| GH_551c816d | in 2026 | 2026-01-01 | 2026-12-31 | Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | 2026-02-19 | earnings_transcript |
| GH_a329742a | pending FDA approval; timing to be determined (2026 or later) | 2026-01-01 | 2027-12-31 | Guardant360 Liquid CDx launch following FDA approval. | Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk. | Ticker | 2026-02-19 | earnings_transcript |
| GH_4e822abd | 2026–2027 timeframe | 2026-07-01 | 2027-12-31 | AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive. | Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative. | Ticker | 2026-02-19 | earnings_transcript |
| GH_17aaaacc | near term (2026) | 2026-01-01 | 2026-12-31 | ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption. | Could drive Shield volumes and broaden market access, supporting volume growth. | Ticker | 2026-02-19 | earnings_transcript |